Origin & tradition
Not traditional as an isolate, though apigenin is abundant in chamomile tea and parsley, both used medicinally for centuries.
Western tradition · Flavonoid
A flavone from parsley and chamomile that inhibits CD38 (NADase) — preserving NAD+ through a complementary mechanism to NMN or NR.
↑ iHerb link is an affiliate link — we may earn a commission at no cost to you.
Not traditional as an isolate, though apigenin is abundant in chamomile tea and parsley, both used medicinally for centuries.
Key active: Apigenin (flavone — CD38 inhibitor & SIRT1 modulator).
Apigenin inhibits CD38, an ectoenzyme that consumes ~60% of cellular NAD+. This creates mechanistic synergy with NMN/NR: more precursor + less degradation. Apigenin also modulates SIRT1, CK2, and NF-κB. Most longevity evidence is preclinical; anti-cancer and anti-inflammatory human trials are ongoing.
Effect summary
| Health outcome | Effect | Magnitude | Grade |
|---|---|---|---|
| CD38 inhibition / NAD+ preservation — Mechanism well-characterized; human outcome data limited | Increases | Minor | C |
| Anxiety / sleep (chamomile) | Decreases | Minor | C |
| Inflammation markers | Decreases | Minor | C |
Grade: A = robust RCTs · B = several RCTs / meta-analysis · C = limited or mixed RCTs · D = observational or early data
Dosage guidance
Apigenin inhibits CD38, an enzyme that consumes NAD+. Chamomile tea is a rich dietary source (~3–5mg per cup). Used by some longevity practitioners to complement NMN/NR by reducing NAD+ degradation. Human trial data is limited.
Informational only — not a prescription or personalised medical advice. Consult a qualified clinician before starting any supplement or medication.
Evidence summary
Strong preclinical (CD38/NAD+/SIRT1); human cancer/anti-inflammatory trials
Apigenin inhibits CD38, an ectoenzyme that consumes ~60% of cellular NAD+. This creates mechanistic synergy with NMN/NR: more precursor + less degradation. Apigenin also modulates SIRT1, CK2, and NF-κB. Most longevity evidence is preclinical; anti-cancer and anti-inflammatory human trials are ongoing.
According to PubMed and ClinicalTrials.gov: trial counts from ClinicalTrials.gov, peer-reviewed literature from PubMed. Counts auto-refresh weekly; last checked 2026-06-12. They include trials across many endpoints, not only longevity.
Informational only — not medical advice, a treatment claim, or a substitute for a qualified clinician. Evidence strength varies; we show mixed and null results on purpose.
Evidence collections
Compare the evidence
The headline NAD+ booster of the longevity world — human trials show it raises blood NAD+ and may support physical function.
The leading NMN alternative — a direct NAD+ precursor with multiple RCTs confirming it safely raises NAD+ levels in humans.
The simplest and cheapest NAD+ precursor — with extensive human trial data in skin aging and DNA repair.
A more bioavailable cousin of resveratrol, often paired with NAD precursors in longevity formulas.
Compare the evidence
Suppliers
Tell us what you need and we will source suppliers for you.